TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00630201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probuphine (buprenorphine implant)
Description: Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
Study: NCT02024737

Intervention type: OTHER
Intervention: MRI lung imaging (not an intervention per se but the focus of the study)
Description: The purpose of this pilot study is to determine short and long term reproducibility of a comprehensive set of functional imaging data; using hyperpolarised gas MRI, conventional MRI and lung physiology measurements in patients with moderate to severe COPD. In addition,how sensitive the imaging techniques are to changes in lung function after treatment with a standard (bronchodilator) inhaler will also be assessed (the bronchodilator foradil is a non-investigative medicinal product as it is a medicine with a known effect which will be used to induce a known response).~This pilot study will serve as a platform for future larger scale studies, aimed at better understanding of and intervention in early COPD.
Study: NCT04037852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic assisted nipple sparing mastectomy
Description: R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic assisted nipple sparing mastectomy
Description: E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional nipple sparing mastectomy
Description: Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
Study: NCT03887169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methionine
Description: Administration of methionine from D1 to D60

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12, B9, B6, C supplementation
Description: In case of hyperhomocysteinemia

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Methionine/homocysteine Dosage
Description: Plasma concentration control of methionine and homocysteine from D0 to D75

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thoracic CT scan
Description: At D60
Study: NCT02550080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone
Description: For the HLA-B\*1301 positive subjects, dapsone will not be administrated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone
Description: For the HLA-B\*1301 positive subjects, dapsone will not be administrated.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA-B*1301
Description: The prospective genetic screening group will be tested before administrating dapsone
Study: NCT04554758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: Bariatric operation will be done by laparoscopic sleeve gastrectomy procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Description: Bariatric operation will be done by laparoscopic Roux-en-Y gastric bypass procedure.
Study: NCT03174288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 24 weeks of exercise treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 24 weeks of exercise treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 24 weeks of spironolactone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 24 weeks of spironolactone
Study: NCT03765229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Oral drug 5 mg taken once weekly for up to nine 3-week (21 day) cycles. Take on an empty stomach i.e., at least 2 hours after a meal and at least 1 hour before the next meal. On days when entinostat is administered on the same day as pembrolizumab, entinostat should be taken before the pembrolizumab infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV starting on Day 22 (cycle 2, Day 1) given every 3 weeks for up to 8 cycles.
Study: NCT01039805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (50 mg)
Description: Cohort 1 = 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (75 mg)
Description: Cohort 2 = 75 mg
Study: NCT01899105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivacaftor
Study: NCT03896178

Intervention type: OTHER
Intervention: None, observational study
Description: None, observational study

Intervention type: OTHER
Intervention: None, observational study
Description: None, observational study

Intervention type: OTHER
Intervention: None, observational study
Description: None, observational study

Intervention type: OTHER
Intervention: None, observational study
Description: None, observational study

Intervention type: OTHER
Intervention: None, observational study
Description: None, observational study
Study: NCT02994641

Intervention type: PROCEDURE
Intervention: COMA Score Assessment

Intervention type: PROCEDURE
Intervention: COMA Score Assessment
Study: NCT04290325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: HMPL-453 tablet
Study: NCT01315795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 90 mg and 120 mg
Description: administration of lanreotide sc every 4 weeks (28 days)
Study: NCT02485418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
Study: NCT01229813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab, erlotinib
Description: bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily
Study: NCT03887169

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abdominal and liver ultrasound.
Description: At D60

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: In case of abnormal neurological examination
Study: NCT01229813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab 7.5 mg/kg body weight every third week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: bevacizumab 7.5 mg/kg body weight every third week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose capecitabine
Description: capecitabine 500 mg twice daily
Study: NCT02256306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma
Description: 1 unit of Plasma From Young Donors (Male, aged 30 or younger)
Study: NCT02704559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20156
Study: NCT03338244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
Study: NCT02181218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT04749498

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Bread
Description: Test breakfast with white bread was served after 12-hours of fasting and participants were asked to consume the meal in full, within 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Wheat Bread
Description: In a crossover design, this bread was served with a standard breakfast to compare other breads.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Barley Bread
Description: In a crossover design, this bread was served with a standard breakfast to compare other breads.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oat Bread
Description: In a crossover design, this bread was served with a standard breakfast to compare other breads.
Study: NCT02886598

Intervention type: DRUG
Intervention: degarelix
Study: NCT02164006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202 + brentuximab vedotin
Description: TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
Study: NCT02420041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Fluoroscopic Guided SIJ injection
Description: * Needle entry point is in the lower one-third of the SIJ~* Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry~* Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a coaxial fashion into the SIJ~* 1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake~* Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine~* Patient observed in recovery bay for 20 minutes and then discharged home

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Sacroiliac Joint Injection
Description: * Sterile preparation (with chlorhexidine) and drape~* Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer~* 3 mL of 1% lidocaine is injected subcutaneously at site of needle entry~* Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not spill out onto sacrum).~* After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.~* Patient observed in recovery bay for 20 minutes and then discharged home

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle
Study: NCT02181218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT02420041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoSite S-nerve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iohexol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone/lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone/lidocaine
Study: NCT01518088

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Dietary fiber will be added to study foods

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Dietary fiber will be added to study foods

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Fiber
Description: Dietary fiber will be added to study foods
Study: NCT01902498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
Study: NCT03049345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Sampling
Description: The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioactive Tracers
Description: see above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue 20 MG/ML
Description: see above
Study: NCT00665223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR16
Description: Capsules will be swallowed whole with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR16
Description: Capsules will be swallowed whole with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules will be swallowed whole with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules will be swallowed whole with water.
Study: NCT01278615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study: NCT04117815

Intervention type: DEVICE
Intervention: Paxman Scalp Cooling System
Description: All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~* Minimum 30 minutes pre-infusion cooling~* Cooling for the duration of chemotherapy infusion~* Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session.

Intervention type: OTHER
Intervention: Alopecia Assessments
Description: Patients (study group and reference group) will be assessed at the following time Points:~* Baseline~* at the half-way Point of the cyles~* at the last CT cycle~* 3 months after completion of Treatment~* 6-9 months after treatment completion~The assesments include the following~* Photographs of the head, which are evaluated using the CTCAEv4.0~* Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire

Intervention type: OTHER
Intervention: Alopecia Assessments
Description: Patients (study group and reference group) will be assessed at the following time Points:~* Baseline~* at the half-way Point of the cyles~* at the last CT cycle~* 3 months after completion of Treatment~* 6-9 months after treatment completion~The assesments include the following~* Photographs of the head, which are evaluated using the CTCAEv4.0~* Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire
Study: NCT01803347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ◦Drug: ASCs. + fibrin glue
Description: Experimental group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fibrin glue
Description: •Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
Study: NCT03980990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Continuation of Metformin
Study: NCT01586975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Description: Aspirin 81mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin >300 mg
Description: Aspirin \>300 mg QD
Study: NCT01432522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 1. Intranasal epinephrine 5 mg /spray~2. Intramuscular epinephrine 0.3 mg~3. Intranasal saline spray
Study: NCT04756206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride 0.5 mg
Description: patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
Study: NCT04502836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preliminary psychological intervention
Description: psychological intervention including providing knowledge and tools for problems solving according to the Choice - Agenda - Resilience - Emotional support (CARE) model . After intervention session patients and their parents will be asked to complete questionnaires
Study: NCT02950181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Description: Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
Study: NCT01152476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: General anesthesia is maintained witn sevoflurane and remifentanil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
Study: NCT00643318

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Stereotactic Radiosurgery
Description: Central tumors defined as \< 2 cm from carina and \< 2 cm from right and left mainstem bronchus and/or \< 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being \> 2 cms from the carina and \> 2 cms from the right and left mainstem bronchus and/or \> 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)
Study: NCT00809913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short treatment (ciprofloxacin)
Description: 7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short treatment (ciprofloxacin)
Description: 7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
Study: NCT02654132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03593330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional Care Programme
Description: These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
Study: NCT00338949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch
Description: Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
Study: NCT04169997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4927
Description: IMP4297 tablet.The starting dose from 100mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos tablet.The starting dose from 100mg QD